Modular Medical (MODD) announced Institutional Review Board approval to conduct an in-house study of its next-generation Pivot insulin delivery system using insulin on people with diabetes. Pursuant to U.S. Food and Drug Administration regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects. The Study will simulate real-world conditions by delivering insulin to adult participants to gather critical data on device function and usability and obtain user feedback. Modular Medical’s Pivot tubeless patch pump aims to enhance accessibility for underserved patients with diabetes and drive market penetration and expansion. Key objectives and potential impacts of the Study include: Assess usability and the patient experience. Collect participant feedback to optimize design for everyday diabetes management
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MODD:
- Modular Medical submits Pivot tubeless patch pump for 510(k) clearance
- Modular Medical announces validation of Pivot controller line
- Modular Medical announces ‘ongoing progress’ to obtain CE Mark
- Modular Medical appoints David Bosshard as head of international operations
- Modular Medical announces exercise of warrants for $4.4M in proceeds